ZL-1310, an Investigational DLL3-Targeted Antibody-Drug …
Oct 24, 2024 · ZL-1310 is a novel ADC in Zai Lab’s growing, global oncology pipeline that targets Delta-like ligand 3 (DLL3), an antigen that is overexpressed in many neuroendocrine tumors, is typically associated with poor clinical outcomes, and is a validated therapeutic target for SCLC.
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 …
2 days ago · ZL-1310 is a novel ADC in Zai Lab’s growing, global oncology pipeline that targets Delta-like ligand 3 (DLL3), an antigen that is overexpressed in many neuroendocrine tumors, is typically associated with poor clinical outcomes, and is a validated therapeutic target for SCLC. ZL-1310 comprises a humanized anti-DLL3 monoclonal antibody linked ...
DLL3-Targeted ADC Produces Responses in Previously Treated ES …
Oct 25, 2024 · Developers designed ZL-1310 as a humanized anti-DLL3 monoclonal antibody that links to a topoisomerase 1 inhibitor. The agent’s design may harness the tumor microenvironment to mitigate limitations associated with first-generation ADCs such as off-target payload toxicity.
FDA grants ODD status to Zai Lab’s lung cancer treatment
2 days ago · The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).. The designation provides the therapy with incentives such as fee waivers and tax credits to support its development, along with the possibility of seven years of market exclusivity upon approval.
DLL3-guided therapies in small-cell lung cancer: from antibody …
May 10, 2024 · An emerging antibody-drug conjugate (ADC), ZL-1310, which utilizes camptothecin derivatives as its payload to target topoisomerase I and methylsulfonylpyrimidine tripeptide as cleavable linker , is currently under clinical investigation for SCLC.
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its ...
Nov 26, 2024 · ZL-1310 comprises a humanized anti-DLL3 antibody and a novel camptothecin derivative as its payload. The compound was designed with a novel linker-payload platform called TMALIN®, which leverages the tumor microenvironment to overcome challenges associated with first-generation ADC therapies.
241P Development and characterization of a novel DLL3-targeting ...
ZL-1310, an innovative ADC targeting DLL3, was developed by leveraging the tumor microenvironment activable linker-payload (TMALIN) platform platform). This ADC comprises a humanized anti-DLL3 antibody, a linker susceptible to protease cleavage, and a novel camptothecin derivative as its payload.
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody …
May 30, 2024 · ZL-1310 is a novel and promising ADC within the Zai Lab global oncology R&D pipeline, targeting the Delta-like ligand 3 (DLL3), a validated therapeutic target in the treatment of small cell lung cancer (SCLC).
Abstract - American Association for Cancer Research
Apr 5, 2024 · ZL-1310 is designed to minimize payload toxicity and improve anti-tumor effectiveness. Methods: This is an open-label, multiple-dose, phase 1 study of ZL-1310 administered to subjects with relapsed/refractory (r/r) metastatic SCLC who have progressed after at least one platinum-based chemotherapy regimen.
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug …
Oct 24, 2024 · ZL-1310 is being tested in patients with previously treated extensive-stage Small Cell Lung Cancer (ES-SCLC) after at least one prior platinum-based chemotherapy regimen.
- Some results have been removed